Literature DB >> 19669126

Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation.

Stefan Barlage1, Carsten Gnewuch, Gerhard Liebisch, Zsuzsanna Wolf, Franz-Xaver Audebert, Thomas Glück, Dieter Fröhlich, Bernhard K Krämer, Gregor Rothe, Gerd Schmitz.   

Abstract

OBJECTIVE: Lipoproteins modulate vascular cell function in inflammation. In this study, we analyzed whether plasma concentrations of lipoproteins and apolipoproteins in human sepsis are related to patient survival and the activation of blood monocytes and platelets.
DESIGN: Observational study.
SETTING: Medical and surgical intensive care units (ICU) of a university hospital. PATIENTS: 151 consecutive patients after sepsis criteria had been met for the first time.
INTERVENTIONS: None. MEASUREMENTS: Plasma lipoproteins, apolipoproteins, platelet CD62P-expression, monocyte HLA-DR-expression, SAPS II-scores (Simplified Acute Physiology Score) and 30-day-mortality were recorded.
RESULTS: Total cholesterol, high-density-lipoprotein (HDL) and low-density-lipoprotein (LDL) cholesterol, apolipoprotein (apo)-AI and apo-B were all found to be significantly lower in non-survivors than in survivors. In contrast to other (apo)lipoproteins, apo-AI and HDL cholesterol further decreased in non-survivors during the ICU stay. Logistic regression analysis revealed apo-AI to be an independent predictor of 30-day-mortality. A significant inverse correlation was found for apo-AI/HDL-cholesterol and platelet activation. Later in the course of the disease, HLA-DR expression on monocytes correlated positively to apo-AI and apo-CI concentrations and inversely to the apo-E concentration.
CONCLUSION: Low apo-AI is independently related to 30-day mortality in human sepsis and the decrease in apo-AI/HDL cholesterol correlates to increased platelet activation. Moreover, changes in apolipoproteins supposed to modulate lipopolysaccharide effects, such as apo-CI and apo-E, correlate to monocyte activation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19669126     DOI: 10.1007/s00134-009-1609-y

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  35 in total

Review 1.  Multiple actions of high-density lipoprotein.

Authors:  Matilda Florentin; Evangelos N Liberopoulos; Anthony S Wierzbicki; Dimitri P Mikhailidis
Journal:  Curr Opin Cardiol       Date:  2008-07       Impact factor: 2.161

2.  Apolipoprotein CI stimulates the response to lipopolysaccharide and reduces mortality in gram-negative sepsis.

Authors:  Jimmy F P Berbée; Caroline C van der Hoogt; Robert Kleemann; Emile F Schippers; Richard L Kitchens; Jaap T van Dissel; Irma A J M Bakker-Woudenberg; Louis M Havekes; Patrick C N Rensen
Journal:  FASEB J       Date:  2006-08-25       Impact factor: 5.191

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis.

Authors:  Jung-Yien Chien; Jih-Shuin Jerng; Chong-Jen Yu; Pan-Chyr Yang
Journal:  Crit Care Med       Date:  2005-08       Impact factor: 7.598

5.  Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis.

Authors:  M Van Oosten; P C Rensen; E S Van Amersfoort; M Van Eck; A M Van Dam; J J Breve; T Vogel; A Panet; T J Van Berkel; J Kuiper
Journal:  J Biol Chem       Date:  2001-01-02       Impact factor: 5.157

6.  Platelet and leukocyte activation correlate with the severity of septic organ dysfunction.

Authors:  Stefan Russwurm; James Vickers; Andreas Meier-Hellmann; Peter Spangenberg; Don Bredle; Konrad Reinhart; Wolfgang Lösche
Journal:  Shock       Date:  2002-04       Impact factor: 3.454

Review 7.  Apolipoproteins modulate the inflammatory response to lipopolysaccharide.

Authors:  Jimmy F P Berbée; Louis M Havekes; Patrick C N Rensen
Journal:  J Endotoxin Res       Date:  2005

8.  Reconstituted high density lipoprotein (rHDL) modulates platelet activity in vitro and ex vivo.

Authors:  P G Lerch; M O Spycher; J E Doran
Journal:  Thromb Haemost       Date:  1998-08       Impact factor: 5.249

9.  Human ApoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice.

Authors:  Yue Li; Ji-Bin Dong; Man-Ping Wu
Journal:  Eur J Pharmacol       Date:  2008-06-16       Impact factor: 4.432

10.  High-density lipoprotein reduces the human monocyte inflammatory response.

Authors:  Andrew J Murphy; Kevin J Woollard; Anh Hoang; Nigora Mukhamedova; Roslynn A Stirzaker; Sally P A McCormick; Alan T Remaley; Dmitri Sviridov; Jaye Chin-Dusting
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-10       Impact factor: 8.311

View more
  46 in total

1.  The role of HDL in innate immunity.

Authors:  Kenneth R Feingold; Carl Grunfeld
Journal:  J Lipid Res       Date:  2010-10-13       Impact factor: 5.922

Review 2.  Lipid testing in infectious diseases: possible role in diagnosis and prognosis.

Authors:  Sebastian Filippas-Ntekouan; Evangelos Liberopoulos; Moses Elisaf
Journal:  Infection       Date:  2017-05-08       Impact factor: 3.553

3.  Dyslipidemia: a prospective controlled randomized trial of intensive glycemic control in sepsis.

Authors:  Sylas B Cappi; Danilo T Noritomi; Irineu T Velasco; Rui Curi; Tatiana C A Loureiro; Francisco G Soriano
Journal:  Intensive Care Med       Date:  2012-02-02       Impact factor: 17.440

4.  Proinflammatory high-density lipoprotein results from oxidized lipid mediators in the pathogenesis of both idiopathic and associated types of pulmonary arterial hypertension.

Authors:  David J Ross; Greg Hough; Susan Hama; Jamil Aboulhosn; John A Belperio; Rajan Saggar; Brian J Van Lenten; Abbas Ardehali; Mansoureh Eghbali; Srinivasa Reddy; Alan M Fogelman; Mohamad Navab
Journal:  Pulm Circ       Date:  2015-12       Impact factor: 3.017

Review 5.  The role of sphingolipids in endothelial barrier function.

Authors:  Peter L Jernigan; Amy T Makley; Richard S Hoehn; Michael J Edwards; Timothy A Pritts
Journal:  Biol Chem       Date:  2015-06       Impact factor: 3.915

6.  Effect of a Probiotic Preparation (VSL#3) on CardiovascularRisk Parameters in Critically-Ill Patients.

Authors:  Sarvin Sanaie; Mehrangiz Ebrahimi-Mameghani; Ata Mahmoodpoor; Kamran Shadvar; Samad Ej Golzari
Journal:  J Cardiovasc Thorac Res       Date:  2013-06-27

7.  Reduction in postoperative high-density lipoprotein cholesterol levels in children undergoing the Fontan operation.

Authors:  Sinai C Zyblewski; W Scott Argraves; Eric M Graham; Elizabeth H Slate; Andrew M Atz; Scott M Bradley; Tim C McQuinn; Brent A Wilkerson; Shane B Wing; Kelley M Argraves
Journal:  Pediatr Cardiol       Date:  2012-03-13       Impact factor: 1.655

8.  Apolipoprotein M Protects Against Lipopolysaccharide-Induced Acute Lung Injury via Sphingosine-1-Phosphate Signaling.

Authors:  Bin Zhu; Guang-Hua Luo; Yue-Hua Feng; Miao-Mei Yu; Jun Zhang; Jiang Wei; Chun Yang; Ning Xu; Xiao-Ying Zhang
Journal:  Inflammation       Date:  2018-03       Impact factor: 4.092

9.  Paraoxonase 1 Activity and Survival in Sepsis Patients.

Authors:  Volkan İnal; Levent Yamanel; Gürhan Taşkın; Serkan Tapan; Bilgin Cömert
Journal:  Balkan Med J       Date:  2015-04-01       Impact factor: 2.021

Review 10.  Year in review in Intensive Care Medicine 2009: I. Pneumonia and infections, sepsis, outcome, acute renal failure and acid base, nutrition and glycaemic control.

Authors:  Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang
Journal:  Intensive Care Med       Date:  2010-01-08       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.